B-ALL

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  

B-ALL
May 2, 2025, 20:26 | Insight
Susanna Fletcher Greer: A V Foundation Researcher May Have Found the End-all to B-ALL
Susanna Fletcher Greer, Chief Scientific Officer of the V Foundation, shared a post on LinkedIn:…
Nov 30, 2024, 15:27 | Insight
Obe-cel CAR T Therapy Achieves High Response Rates in R/R B-cell ALL: FELIX Trial Results
Trial results supported recent FDA approval for patients with relapsed/refractory disease Patients with relapsed or…
Nov 16, 2024, 20:28 | Insight
Naveen Pemmaraju: Our new report on DDX for mediastinal mass in patient with B-ALL
Naveen Pemmaraju, Professor and Director of BPDCN Program at the Department of Leukemia at the…
May 29, 2024, 15:16 | Blog
Chen Lin: Updated results from FELIX for obecabtagene autoleucel in B-ALL by Elias Jabbour et al
Chen Lin, Assistant Professor at Duke Cancer Institute, shared on X/Twitter: "Updated results from FELIX for…
May 21, 2024, 07:10 | Blog
Nitin Jain: Brief summary slide with some general concepts about assay depth
Nitin Jain, Professor of Medicine in the Department of Leukemia at The University of Texas MD…
May 15, 2024, 14:47 | Drugs
Hagop Kantarjian: New research is expanding inotuzumab use into frontline, for MRD+, and in combination with blinatumomab
Nicholas Short, Associate Professor at the Department of Leukemia at MD Anderson Cancer Center, shared…
May 14, 2024, 10:12 | Blog
Aaron Goodman: CD markers simplified!
Quoting Aaron Goodman on X: “CD markers simplified! CD34+ = Blast CD3+ = T-cell CD19+ = B-cell…
Jan 16, 2024, 11:37 | Insight
Jayastu Senapati: Check out our SOHO State of the Art Review on Acute Lymphoblastic Leukemia
Jayastu Senapati, Assistant Professor at the Department of Leukemia at MD Anderson Cancer Center, shared…
Aug 31, 2023, 18:52 | Insight
Nitin Jain: Excited to share preclinical data with CRLF2 bispecific antibody for CRLF2-rearranged B-ALL.
Quoting Nitin Jain, the Director of Leukemia CAR-T Program at the MD Anderson Cancer Center:…
All: 9 Posts: 1 - 100
Special Coverage